Join WhatsApp

Folow Facebook

Subscribe YouTube

Follow Instagram

New Delhi: US President Donald Trump’s move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 is unlikely to have an immediate impact on Indian exports, as it will affect only patented and branded products, not generic medicines, pharma industry players said on Friday.

Indian Pharmaceutical Alliance (IPA), which represents 23 leading Indian pharmaceutical firms, including Dr Reddy’s Laboratories, Sun Pharma, Lupin, and Zydus Lifesciences, noted that Trump’s latest tariff will not have implications for the generic drugmakers.

In his post on social media platform Truth Social, Trump wrote, “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Pr

See Full Page